The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy.
Open accessAbstract
Verapamil is extremely effective in the treatment of patients with hypertrophic cardiomyopathy. However, the basic physiologic actions of the drug may lead to serious adverse effects. An appreciation of this and an understanding of when these adverse effects are most likely to occur will minimize the potential of verapamil to cause serious complications in patients with hypertrophic cardiomyopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verapamil: A Review of its Pharmacological Properties and Therapeutic Use1
Singh, B. N., Ellrodt, G., & Peter, C. T. (1978) · Drugs · doi:10.2165/00003495-197815030-00001 · Cited by 832
HENRY, W. L., CLARK, C. E., & EPSTEIN, S. E. (1973) · Circulation · doi:10.1161/01.cir.47.2.225 · Cited by 520
Self-citationBonow, R. O., Rosing, D. R., Bacharach, S. L., Green, M. V., Kent, K. M., Lipson, L. C., Maron, B. J., Leon, M. B., & Epstein, S. E. (1981) · Circulation · doi:10.1161/01.cir.64.4.787 · Cited by 393
Self-citationWIT, A. L., & CRANEFIELD, P. F. (1974) · Circulation Research · doi:10.1161/01.res.35.3.413 · Cited by 281
ZIPES, D. P., & FISCHER, J. C. (1974) · Circulation Research · doi:10.1161/01.res.34.2.184 · Cited by 278
Rosing, D. R., Kent, K. M., Maron, B. J., & Epstein, S. E. (1979) · Circulation · doi:10.1161/01.cir.60.6.1208 · Cited by 246
Self-citationRosing, D. R., Kent, K. M., Borer, J. S., Seides, S. F., Maron, B. J., & Epstein, S. E. (1979) · Circulation · doi:10.1161/01.cir.60.6.1201 · Cited by 230
Self-citationTreatment of hypertrophic obstructive cardiomyopathy with verapamil.
Kaltenbach, M., Hopf, R., Kober, G., Bussmann, W. D., Keller, M., & Petersen, Y. (1979) · Heart · doi:10.1136/hrt.42.1.35 · Cited by 213
Rosing, D. R., Condit, J. R., Maron, B. J., Kent, K. M., Leon, M. B., Bonow, R. O., Lipson, L. C., & Epstein, S. E. (1981) · The American Journal of Cardiology · doi:10.1016/0002-9149(81)90086-2 · Cited by 172
Self-citationAtterh�g, J. H., & Ekelund, L. G. (1975) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562656 · Cited by 62
Cited by
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Hypertrophic Cardiomyopathy: A Systematic Review
Maron, B. J. (2002) · JAMA · doi:10.1001/jama.287.10.1308 · Cited by 2,224
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318223e2bd · Cited by 2,104
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.011 · Cited by 1,276
The Management of Hypertrophic Cardiomyopathy
Spirito, P., Seidman, C. E., McKenna, W. J., & Maron, B. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703133361107 · Cited by 1,007
Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review
Wigle, E. D., Sasson, Z., Henderson, M. A., Ruddy, T. D., Fulop, J., Rakowski, H., & Williams, W. G. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(85)90024-6 · Cited by 823
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318223e230 · Cited by 818
Hypertrophic Cardiomyopathy: Clinical Spectrum and Treatment
Wigle, E. D., Rakowski, H., Kimball, B. P., & Williams, W. G. (1995) · Circulation · doi:10.1161/01.cir.92.7.1680 · Cited by 778
Elliott, P., & McKenna, W. J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16358-7 · Cited by 498
Frequency and Phenotypes of Familial Dilated Cardiomyopathy
Grünig, E., Tasman, J. A., Kücherer, H., Franz, W., Kübler, W., & Katus, H. A. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00434-8 · Cited by 435
Sherrid, M. V., Barac, I., McKenna, W. J., Elliott, P. M., Dickie, S., Chojnowska, L., Casey, S., & Maron, B. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.012 · Cited by 410
Maron, B. J., Bonow, R. O., Cannon, R. O., Leon, M. B., & Epstein, S. E. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704023161405 · Cited by 370
Self-citation2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., Mahrholdt, H., et al. (2014) · Kardiologia Polska · doi:10.5603/kp.2014.0212 · Cited by 341
Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man.
Packer, M., Meller, J., Medina, N., Yushak, M., Smith, H., Holt, J., Guererro, J., Todd, G. D., McAllister, R. G., & Gorlin, R. (1982) · Circulation · doi:10.1161/01.cir.65.4.660 · Cited by 332
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.10.020 · Cited by 322
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.10.825 · Cited by 279
Alpert, M. A., & Hashimi, M. W. (1993) · The American Journal of the Medical Sciences · doi:10.1097/00000441-199308000-00011 · Cited by 245
Sherrid, M. V., Shetty, A., Winson, G., Kim, B., Musat, D., Alviar, C. L., Homel, P., Balaram, S. K., & Swistel, D. G. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000122 · Cited by 178
Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression.
Caforio, A. L., Goldman, J. H., Baig, M. K., Haven, A. J., Dalla Libera, L., Keeling, P. J., & McKenna, W. J. (1997) · Heart · doi:10.1136/hrt.77.1.62 · Cited by 80
Autoimmunity to alpha myosin in a subset of patients with idiopathic dilated cardiomyopathy.
Goldman, J. H., Keeling, P. J., Warraich, R. S., Baig, M. K., Redwood, S. R., Dalla Libera, L., Sanderson, J. E., Caforio, A. L., & McKenna, W. J. (1995) · Heart · doi:10.1136/hrt.74.6.598 · Cited by 62
The Effects of Slow Channel Blockers and Beta Blockers on Atrioventricular Nodal Conduction
Prystowsky, E. N. (1988) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1988.tb03095.x · Cited by 34
Current management of hypertrophic cardiomyopathy
Sikand, N., Stendahl, J., Sen, S., Lampert, R., & Day, S. (2025) · BMJ · doi:10.1136/bmj-2023-077274 · Cited by 26
Sirak, T. E., & Sherrid, M. V. (2008) · Chest · doi:10.1378/chest.07-1188 · Cited by 13
Lifestyle Modification and Medical Management of Hypertrophic Cardiomyopathy
Heitner, S. B., & Fischer, K. L. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2018.08.004 · Cited by 3
Metadata
- Authors
- Epstein, S. E., & Rosing, D. R.
- Venue
- Circulation
- Published
- 1981-09
- Volume
- 64
- Issue
- 3
- Pages
- 437-441
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2092895033
- Cited by
- 271
- References
- 11
- FWCI
- 16.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.